Synopsis

Source of validity: Scientific
Rating (out of 5): 2

β-Nicotinamide mononucleotide (NMN) is a precursor to nicotinamide adenine dinucleotide (NAD+), a molecule essential for cellular energy metabolism and DNA repair. The scientific rationale for NMN's use in peripheral neuropathy is primarily based on preclinical studies. Animal models of diabetic and chemotherapy-induced neuropathy have shown that NMN supplementation can increase NAD+ levels in nerve tissues, mitigate oxidative stress, reduce inflammation, and improve mitochondrial function, which are all factors implicated in the pathogenesis of peripheral neuropathy. For example, several studies in mice have demonstrated that NMN administration can preserve nerve structure, prevent loss of sensory function, and reduce pain behaviors.

Despite these promising results in laboratory settings, clinical evidence in humans remains extremely limited. As of mid-2024, there are no large, well-controlled clinical trials directly assessing NMN’s efficacy in treating or preventing peripheral neuropathy in humans. Most human research with NMN has focused on its safety, pharmacokinetics, or potential to improve markers of aging and metabolic health, rather than direct neuropathic outcomes. Thus, while the mechanistic and animal data are encouraging and provide a scientific basis for further investigation, robust clinical validation is lacking. Current use is based on preclinical science rather than established clinical benefit, so the evidence rating is low. NMN should not be considered a proven therapy for peripheral neuropathy outside of research settings.

More about β-nicotinamide mononucleotide (NMN)
More about Peripheral Neuropathy

Other ingredients used for Peripheral Neuropathy

Other health conditions supported by β-nicotinamide mononucleotide (NMN)

Products containing β-nicotinamide mononucleotide (NMN)

Designs For Health Liposomal NMN Synergy 1.7 fl oz (50 ml) liquid. Nonreturnable item.